Phase 1 study

CAMBRIDGE, Mass., April 13, 2026 Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease, has announced that the...

CANTANHEDE, Portugal — December 22, 2025 — Mondego Bio has announced the formal selection of ZE00-0388, a highly selective...